Ghent, BELGIUM – 25 June 2020 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces today that 644,287 existing shares have been admitted to listing and trading on the regulated market of Euronext Brussels. The...Read More